Filing Flows › Zenas BioPharma (ZBIO) › Q4 2024
Zenas BioPharma (ZBIO) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 11, 2025
Zenas BioPharma (ZBIO) reported revenue of $5.0M for the fourth quarter 2024 (Q4 2024).
Zenas BioPharma, Q4 2024: revenue $5.0M, net loss $52.6M, operating cash flow −$38.6M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $5.0M | — | — |
| Operating profit | −$55.6M | — | — |
| Net earnings | −$52.6M | — | — |
| Operating cash flow | −$38.6M | — | — |
What changed
Revenue was $5.0M in Q4 2024.
Operating costs exceeded revenue by $55.6M, an operating margin of -1112.5%. The quarter ended with a net loss of $52.6M.
Operating cash flow was −$38.6M. Non-cash charges added back $33K of depreciation and $5.5M of share-based compensation. Working capital and other items added $8.5M. Capital expenditures of $74K exceeded it, leaving free cash flow of −$38.6M.
Questions
What was Zenas BioPharma's revenue in the fourth quarter 2024?
Zenas BioPharma (ZBIO) reported revenue of $5.0M for the fourth quarter 2024 (Q4 2024).
Source: Zenas BioPharma 10-K on SEC EDGAR.